JP2018044008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018044008A5 JP2018044008A5 JP2017243651A JP2017243651A JP2018044008A5 JP 2018044008 A5 JP2018044008 A5 JP 2018044008A5 JP 2017243651 A JP2017243651 A JP 2017243651A JP 2017243651 A JP2017243651 A JP 2017243651A JP 2018044008 A5 JP2018044008 A5 JP 2018044008A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- ethyl
- pyrimidin
- chloro
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 18
- -1 —OH Chemical group 0.000 claims 18
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 13
- 102000038030 PI3Ks Human genes 0.000 claims 12
- 108091007960 PI3Ks Proteins 0.000 claims 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000006601 (C1-C3) alkylcarbamyl group Chemical group 0.000 claims 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 5
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- CEECNMYKERBUGO-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 CEECNMYKERBUGO-UHFFFAOYSA-N 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- RYYHOGBWUDOVBW-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RYYHOGBWUDOVBW-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- YGGWPDLYLUHWIQ-UHFFFAOYSA-N n,n-dimethylpyridine-2-carboxamide Chemical compound CN(C)C(=O)C1=CC=CC=N1 YGGWPDLYLUHWIQ-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 claims 1
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims 1
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 1
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- VBCPGZBXELQVJW-UHFFFAOYSA-N 1-[1-[3-(6-aminopyridin-3-yl)-5-chloro-2-methoxy-4-methylphenyl]ethyl]-3-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(N)N=C1 VBCPGZBXELQVJW-UHFFFAOYSA-N 0.000 claims 1
- VZCBKGOVKCOFDS-UHFFFAOYSA-N 2-[5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridin-2-yl]oxyethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(OCCO)N=C1 VZCBKGOVKCOFDS-UHFFFAOYSA-N 0.000 claims 1
- UXTGQWWQMSXIHY-UHFFFAOYSA-N 2-[[5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]pyridin-2-yl]amino]ethanol Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(NCCO)N=C1 UXTGQWWQMSXIHY-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- DZTKLUFVTZFHFJ-UHFFFAOYSA-N 3-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-N,N-dimethylpyridine-2-carboxamide Chemical compound NC1=C2C(=NC=N1)N(N=C2C)C(C)C=2C(=C(C(=C(C2)Cl)C)C=2C(=NC=CC2)C(=O)N(C)C)OC DZTKLUFVTZFHFJ-UHFFFAOYSA-N 0.000 claims 1
- VJJSELYTDOGDNE-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-(2-hydroxyethyl)-n-methylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=NC(C(=O)N(C)CCO)=C1 VJJSELYTDOGDNE-UHFFFAOYSA-N 0.000 claims 1
- JAOSUCRDSSWHBL-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-cyanopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C#N)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 JAOSUCRDSSWHBL-UHFFFAOYSA-N 0.000 claims 1
- RRSCRMHZMWUSFN-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-cyclopropylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3CC3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RRSCRMHZMWUSFN-UHFFFAOYSA-N 0.000 claims 1
- LWRCOZZUEDSSRB-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-ethylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LWRCOZZUEDSSRB-UHFFFAOYSA-N 0.000 claims 1
- MICRYOZLKDGIIJ-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(I)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MICRYOZLKDGIIJ-UHFFFAOYSA-N 0.000 claims 1
- OFKSVBCPWKARPM-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-(2,2-difluoroethoxy)-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound N1=C(C)C2=C(N)N=CN=C2N1C(C)C(C=1OCC(F)F)=CC(Cl)=C(C)C=1C1=CC=C(C(=O)N(C)C)N=C1 OFKSVBCPWKARPM-UHFFFAOYSA-N 0.000 claims 1
- SPDKDKKGRGWOLC-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)NC)N=C1 SPDKDKKGRGWOLC-UHFFFAOYSA-N 0.000 claims 1
- ONBNCONPECJPDM-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(C)=N2)=C1OC ONBNCONPECJPDM-UHFFFAOYSA-N 0.000 claims 1
- MRVLFHBXSHLHOL-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-methylpyrazolo[4,3-c]pyridin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=CC=NC(N)=C3C(C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MRVLFHBXSHLHOL-UHFFFAOYSA-N 0.000 claims 1
- POXLGQURDCNRHS-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 POXLGQURDCNRHS-UHFFFAOYSA-N 0.000 claims 1
- YXXAZOUQFXBZTQ-UHFFFAOYSA-N 5-[3-[1-(4-amino-3-pyridin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=CN=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 YXXAZOUQFXBZTQ-UHFFFAOYSA-N 0.000 claims 1
- NHMULOGKNRTRLR-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 NHMULOGKNRTRLR-UHFFFAOYSA-N 0.000 claims 1
- MKJFFPOJZAUGHO-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MKJFFPOJZAUGHO-UHFFFAOYSA-N 0.000 claims 1
- MYTVYESWXXZGCZ-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MYTVYESWXXZGCZ-UHFFFAOYSA-N 0.000 claims 1
- KBNSWEWQWKDWCH-UHFFFAOYSA-N 5-[3-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=C(C)C(Cl)=CC(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)=C1OC KBNSWEWQWKDWCH-UHFFFAOYSA-N 0.000 claims 1
- RCULREUPLKRTQM-UHFFFAOYSA-N 5-[3-[1-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RCULREUPLKRTQM-UHFFFAOYSA-N 0.000 claims 1
- NCKZBAHNOUNLOC-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1-methylpyrazol-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=NN(C)C=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 NCKZBAHNOUNLOC-UHFFFAOYSA-N 0.000 claims 1
- YUPRTAQNMSAZLS-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1-methylpyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CN(C)N=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 YUPRTAQNMSAZLS-UHFFFAOYSA-N 0.000 claims 1
- SLEODHBJUISKGK-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-N,N-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CNN=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 SLEODHBJUISKGK-UHFFFAOYSA-N 0.000 claims 1
- LQXVADVQSDQOEW-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(1h-pyrazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=NNC=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LQXVADVQSDQOEW-UHFFFAOYSA-N 0.000 claims 1
- RPANFZBTBQXCEP-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(2-aminopyrimidin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC(N)=NC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RPANFZBTBQXCEP-UHFFFAOYSA-N 0.000 claims 1
- COEMEMLQEMXAPG-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(F)C=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 COEMEMLQEMXAPG-UHFFFAOYSA-N 0.000 claims 1
- FTBLQBUNWWAOJJ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=CC(F)=CC=3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 FTBLQBUNWWAOJJ-UHFFFAOYSA-N 0.000 claims 1
- DUXSSDXCLZIENR-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(5-cyanopyridin-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(C=NC=3)C#N)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 DUXSSDXCLZIENR-UHFFFAOYSA-N 0.000 claims 1
- PFCWFOYSXIUQJD-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(difluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C(F)F)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 PFCWFOYSXIUQJD-UHFFFAOYSA-N 0.000 claims 1
- XVIFKEIMNFEGHE-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(fluoromethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CF)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 XVIFKEIMNFEGHE-UHFFFAOYSA-N 0.000 claims 1
- OIQDMTOTTQKSIQ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(hydroxymethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CO)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 OIQDMTOTTQKSIQ-UHFFFAOYSA-N 0.000 claims 1
- RJLOXSYBHFJOBP-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-(methylaminomethyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CNC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 RJLOXSYBHFJOBP-UHFFFAOYSA-N 0.000 claims 1
- IDJOZOUOJMRPMD-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[(dimethylamino)methyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(CN(C)C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 IDJOZOUOJMRPMD-UHFFFAOYSA-N 0.000 claims 1
- LODIZXIHZIZZJF-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[1-(2-hydroxyethyl)pyrazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C3=CN(CCO)N=C3)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 LODIZXIHZIZZJF-UHFFFAOYSA-N 0.000 claims 1
- MJPPETLGDRBERR-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[5-(dimethylcarbamoyl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=C(C=NC=3)C(=O)N(C)C)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 MJPPETLGDRBERR-UHFFFAOYSA-N 0.000 claims 1
- ONVRGXQBLJXQAQ-UHFFFAOYSA-N 5-[3-[1-[4-amino-3-[6-(methylcarbamoyl)pyridin-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-5-chloro-2-ethoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C=3C=NC(=CC=3)C(=O)NC)=N2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 ONVRGXQBLJXQAQ-UHFFFAOYSA-N 0.000 claims 1
- STPOUNVLXXQXDX-UHFFFAOYSA-N 5-[3-[1-[4-amino-5-oxo-6-(1h-pyrazol-4-yl)pyrido[2,3-d]pyrimidin-8-yl]ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C(C3=CNN=C3)=C2)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 STPOUNVLXXQXDX-UHFFFAOYSA-N 0.000 claims 1
- QMUKEAJHEZKJBD-UHFFFAOYSA-N 5-[3-[1-[[6-amino-5-(2,2-difluoroethanimidoyl)pyrimidin-4-yl]amino]ethyl]-5-chloro-2-methoxy-6-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)NC=2C(=C(N)N=CN=2)C(=N)C(F)F)C=C(Cl)C(C)=C1C1=CC=C(C(=O)N(C)C)N=C1 QMUKEAJHEZKJBD-UHFFFAOYSA-N 0.000 claims 1
- ULQGXBVWPAKWKK-CYBMUJFWSA-N 5-[5-[(1R)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-methoxyphenyl]-N,N-dimethylpyridine-2-carboxamide Chemical compound COc1c(cc(Cl)c(C#N)c1-c1ccc(nc1)C(=O)N(C)C)[C@@H](C)n1nc(C)c2c(N)ncnc12 ULQGXBVWPAKWKK-CYBMUJFWSA-N 0.000 claims 1
- HJSUGXVDZRGDIL-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-cyano-6-ethoxy-3-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 HJSUGXVDZRGDIL-UHFFFAOYSA-N 0.000 claims 1
- HTZQCUXDUVHSIR-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-2-cyano-6-methoxy-3-methylphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound COC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(C)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 HTZQCUXDUVHSIR-UHFFFAOYSA-N 0.000 claims 1
- WKGUYEULKUKCFJ-UHFFFAOYSA-N 5-[5-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 WKGUYEULKUKCFJ-UHFFFAOYSA-N 0.000 claims 1
- VHCJXZTZACMRTL-UHFFFAOYSA-N 5-[5-[1-(4-amino-5-oxopyrido[2,3-d]pyrimidin-8-yl)ethyl]-3-chloro-2-cyano-6-ethoxyphenyl]-n,n-dimethylpyridine-2-carboxamide Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(=O)C=C2)C=C(Cl)C(C#N)=C1C1=CC=C(C(=O)N(C)C)N=C1 VHCJXZTZACMRTL-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530866P | 2011-09-02 | 2011-09-02 | |
| US61/530,866 | 2011-09-02 | ||
| US201261594882P | 2012-02-03 | 2012-02-03 | |
| US61/594,882 | 2012-02-03 | ||
| US201261677445P | 2012-07-30 | 2012-07-30 | |
| US61/677,445 | 2012-07-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248325A Division JP6266743B2 (ja) | 2011-09-02 | 2016-12-21 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201775A Division JP6574039B2 (ja) | 2011-09-02 | 2018-10-26 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018044008A JP2018044008A (ja) | 2018-03-22 |
| JP2018044008A5 true JP2018044008A5 (enExample) | 2018-05-10 |
| JP6427257B2 JP6427257B2 (ja) | 2018-11-21 |
Family
ID=47071429
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528654A Active JP6067709B2 (ja) | 2011-09-02 | 2012-08-31 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2016191928A Active JP6263591B2 (ja) | 2011-09-02 | 2016-09-29 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2016248325A Active JP6266743B2 (ja) | 2011-09-02 | 2016-12-21 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2017243651A Active JP6427257B2 (ja) | 2011-09-02 | 2017-12-20 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2018201775A Active JP6574039B2 (ja) | 2011-09-02 | 2018-10-26 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2019148821A Active JP7038685B2 (ja) | 2011-09-02 | 2019-08-14 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2021210253A Active JP7384891B2 (ja) | 2011-09-02 | 2021-12-24 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2023191694A Active JP7714616B2 (ja) | 2011-09-02 | 2023-11-09 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2025119353A Pending JP2025142039A (ja) | 2011-09-02 | 2025-07-16 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528654A Active JP6067709B2 (ja) | 2011-09-02 | 2012-08-31 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2016191928A Active JP6263591B2 (ja) | 2011-09-02 | 2016-09-29 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2016248325A Active JP6266743B2 (ja) | 2011-09-02 | 2016-12-21 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201775A Active JP6574039B2 (ja) | 2011-09-02 | 2018-10-26 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2019148821A Active JP7038685B2 (ja) | 2011-09-02 | 2019-08-14 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2021210253A Active JP7384891B2 (ja) | 2011-09-02 | 2021-12-24 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2023191694A Active JP7714616B2 (ja) | 2011-09-02 | 2023-11-09 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
| JP2025119353A Pending JP2025142039A (ja) | 2011-09-02 | 2025-07-16 | Ｐｉ３ｋ阻害剤としてのヘテロシクリルアミン |
Country Status (37)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177384A1 (en) | 2009-06-29 | 2012-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
| US8680108B2 (en) * | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| PL3196202T3 (pl) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corporation | Heterocykloaminy jako inhibitory pi3k |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| CA2889905A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| ES2941292T3 (es) | 2013-01-15 | 2023-05-19 | Incyte Holdings Corp | Tiazolecarboxamidas y compuestos de piridinecarboxamida útiles como inhibidores de PIM quinasa |
| TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
| ES2896882T3 (es) | 2014-02-03 | 2022-02-28 | Quadriga Biosciences Inc | Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos |
| CN106132406B (zh) * | 2014-02-03 | 2020-03-27 | 夸德里加生物科学公司 | 作为化疗剂的β-取代的γ-氨基酸和类似物 |
| NZ725778A (en) * | 2014-04-08 | 2023-04-28 | Incyte Holdings Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| MD3831833T2 (ro) | 2015-02-27 | 2023-04-30 | Incyte Holdings Corp | Procedee pentru prepararea unui inhibitor PI3K |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| EP3269367B1 (en) * | 2015-03-11 | 2020-10-07 | Riken | Therapeutic agent for intractable leukemia |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105592A1 (es) | 2015-08-03 | 2017-10-18 | Quadriga Biosciences Inc | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| AR107293A1 (es) | 2016-01-05 | 2018-04-18 | Incyte Corp | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g |
| IL261957B (en) | 2016-03-28 | 2022-07-01 | Incyte Corp | Pyrrolotriazine compounds as TAM inhibitors |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| JOP20200081A1 (ar) | 2017-09-27 | 2020-04-30 | Incyte Corp | أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam |
| MD3697789T2 (ro) | 2017-10-18 | 2022-02-28 | Incyte Corp | Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| DK3813800T3 (da) | 2018-06-29 | 2025-06-02 | Incyte Corp | Formuleringer af en axl/mer-hæmmer |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
| WO2021001743A1 (en) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Translation inhibitors and uses thereof |
| WO2021158891A1 (en) | 2020-02-06 | 2021-08-12 | Incyte Corporation | Salts and solid forms and processes of preparing a pi3k inhibitor |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| EP4251138A1 (en) | 2020-11-30 | 2023-10-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
| WO2024220380A2 (en) * | 2023-04-16 | 2024-10-24 | Totus Medicines Inc. | Pi3k assays and probe compounds therein |
| US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
Family Cites Families (302)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3169967A (en) | 1957-11-14 | 1965-02-16 | Ciba Geigy Corp | Methyl o-lower alkanoyl-reserpates |
| US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| DE1770420U (de) | 1958-02-27 | 1958-07-17 | Tara Union G M B H | Blumentopf aus kunststoff. |
| US3506643A (en) | 1966-12-09 | 1970-04-14 | Max Thiel | N**6-aralkyl-adenosine derivatives |
| DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
| US3814251A (en) | 1972-08-09 | 1974-06-04 | Sperry Rand Corp | Power transmission |
| US3962443A (en) | 1972-08-14 | 1976-06-08 | Dainippon Pharmaceutical Co., Ltd. | Antibacterial pharmaceutical compositions and processes for preparation thereof |
| DE2248232A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine |
| AR204003A1 (es) | 1973-04-03 | 1975-11-12 | Dainippon Pharmaceutical Co | Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables |
| US3936454A (en) | 1973-08-14 | 1976-02-03 | Warner-Lambert Company | 5-Amino-4-chloro-6-(substituted amino)-pyrimidines |
| US3862189A (en) | 1973-08-14 | 1975-01-21 | Warner Lambert Co | Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents |
| DK3375A (enExample) | 1974-01-25 | 1975-09-15 | Ciba Geigy Ag | |
| JPS587626B2 (ja) | 1974-02-13 | 1983-02-10 | 大日本製薬株式会社 | ナフチリジン オヨビ キノリンユウドウタイノセイホウ |
| JPS50111080U (enExample) | 1974-02-21 | 1975-09-10 | ||
| JPS5625234Y2 (enExample) | 1976-01-17 | 1981-06-15 | ||
| JPS5359663A (en) | 1976-11-09 | 1978-05-29 | Sumitomo Chem Co Ltd | 2-halogeno methyl indole derivatives and process for praparation of the same |
| JPS52106897A (en) | 1977-01-10 | 1977-09-07 | Dainippon Pharmaceut Co Ltd | Synthesis of piperazine derivatives |
| JPS5392767A (en) | 1977-01-27 | 1978-08-15 | Sumitomo Chem Co Ltd | Preparation of 2-phthalimidomethylindole derivatives |
| JPS5625234A (en) | 1979-08-02 | 1981-03-11 | Hitachi Denshi Ltd | Dropout display system |
| JPS56123981U (enExample) | 1980-02-20 | 1981-09-21 | ||
| JPS56123981A (en) | 1981-02-23 | 1981-09-29 | Dainippon Pharmaceut Co Ltd | Preparation of 1,4-disubstituted piperazine |
| JPS5883698A (ja) | 1981-11-13 | 1983-05-19 | Takeda Chem Ind Ltd | キノン化合物およびその製造法 |
| JPS5883698U (ja) | 1981-11-27 | 1983-06-06 | 石川島播磨重工業株式会社 | 熱交換器 |
| JPS58162949A (ja) | 1982-03-20 | 1983-09-27 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
| JPS6067709U (ja) | 1983-10-14 | 1985-05-14 | 三洋電機株式会社 | ヘア−ドライヤ− |
| JPS60140373U (ja) | 1984-02-28 | 1985-09-17 | 東洋ハ−ネス株式会社 | ワイヤハ−ネスのア−ス構造 |
| JPS6190153A (ja) | 1984-10-09 | 1986-05-08 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS6263591U (enExample) | 1985-06-29 | 1987-04-20 | ||
| JPS62103640A (ja) | 1985-07-18 | 1987-05-14 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
| JPS635783Y2 (enExample) | 1985-10-17 | 1988-02-17 | ||
| JPS62103640U (enExample) | 1985-12-18 | 1987-07-02 | ||
| JPH07119970B2 (ja) | 1986-04-18 | 1995-12-20 | 富士写真フイルム株式会社 | 画像形成方法 |
| JPS6310746A (ja) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
| CA1324609C (en) | 1986-07-30 | 1993-11-23 | Eastman Kodak Company | Photographic element and process |
| JPS6427257U (enExample) | 1987-08-11 | 1989-02-16 | ||
| US4861701A (en) | 1987-10-05 | 1989-08-29 | Eastman Kodak Company | Photographic element and process comprising a compound which comprises two timing groups in sequence |
| AT388372B (de) | 1987-10-08 | 1989-06-12 | Tanabe Seiyaku Co | Neue naphthalinderivate und sie enthaltende pharmazeutika |
| JPH01250316A (ja) | 1987-12-28 | 1989-10-05 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
| EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
| US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
| JPH054831Y2 (enExample) | 1988-11-22 | 1993-02-08 | ||
| CA2053863C (en) | 1990-04-25 | 1996-10-29 | Keizo Tanikawa | Pyridazinone derivatives |
| SU1712359A1 (ru) | 1990-05-07 | 1992-02-15 | Уфимский Нефтяной Институт | Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR |
| EP0464612B1 (en) | 1990-06-28 | 1998-05-13 | Fuji Photo Film Co., Ltd. | Silver halide photographic materials |
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| JP3108483B2 (ja) | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
| HUT64064A (en) | 1992-02-13 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| WO1993022291A1 (en) | 1992-04-24 | 1993-11-11 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal aminopyrimidines |
| TW229140B (enExample) | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
| FR2714907B1 (fr) | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
| US6342501B1 (en) | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
| JPH0987282A (ja) | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
| JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
| JPH1025294A (ja) | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
| CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| NZ329798A (en) | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| JPH10231297A (ja) | 1997-02-20 | 1998-09-02 | Japan Energy Corp | 新規なアデニン−１−ｎ−オキシド誘導体およびその医薬用途 |
| WO1999024432A1 (fr) | 1997-11-12 | 1999-05-20 | Mitsubishi Chemical Corporation | Derives de purine et medicament les renfermant en tant qu'ingredient actif |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| HRP20000552A2 (en) | 1998-02-25 | 2001-04-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| CN1298404A (zh) | 1998-02-25 | 2001-06-06 | 遗传研究所有限公司 | 磷脂酶a2的抑制剂 |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| SK16352000A3 (sk) | 1998-05-04 | 2002-07-02 | Zentaris Ag | Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny |
| AU3851199A (en) | 1998-05-26 | 1999-12-13 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic indole derivatives and mono- or diazaindole derivatives |
| JP3997651B2 (ja) | 1998-06-24 | 2007-10-24 | コニカミノルタホールディングス株式会社 | 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液 |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| ATE256677T1 (de) | 1998-08-25 | 2004-01-15 | Uab Research Foundation | Inhibitoren der bakteriellen nad synthetase |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| IL144675A0 (en) | 1999-02-01 | 2002-05-23 | Cv Therapeutics Inc | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| JP2000281654A (ja) | 1999-03-26 | 2000-10-10 | Tanabe Seiyaku Co Ltd | イソキノリン誘導体 |
| DE19932571A1 (de) | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
| JP2001151771A (ja) | 1999-09-10 | 2001-06-05 | Kyowa Hakko Kogyo Co Ltd | 含窒素芳香族複素環誘導体 |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| EP1138328A1 (en) | 2000-03-29 | 2001-10-04 | Eli Lilly And Company Limited | Naphthalene derivatives as CNS drugs |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| HU230396B1 (hu) | 2000-06-28 | 2016-04-28 | Smithkline Beecham Plc | Nedves őrlési eljárás |
| CN1331340A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸 |
| EP1300398B1 (en) | 2000-07-05 | 2006-04-05 | Astellas Pharma Inc. | Propane-1,3-dione derivatives |
| FR2814073B1 (fr) | 2000-09-21 | 2005-06-24 | Yang Ji Chemical Company Ltd | Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition |
| DOP2002000334A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| CA2439666A1 (en) | 2001-03-01 | 2002-09-12 | Shionogi & Co., Ltd. | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
| US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
| WO2002088124A2 (en) | 2001-04-27 | 2002-11-07 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
| CZ294535B6 (cs) | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| IL160707A0 (en) | 2001-09-26 | 2004-08-31 | Bayer Pharmaceuticals Corp | 1, 8-naphthyridine derivatives as antidiabetics |
| JP4459619B2 (ja) | 2001-10-02 | 2010-04-28 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物 |
| CA2462657C (en) | 2001-10-30 | 2011-04-26 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| WO2003041642A2 (en) | 2001-11-09 | 2003-05-22 | Enzon, Inc. | Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| ES2291543T3 (es) | 2001-12-06 | 2008-03-01 | MERCK & CO., INC. | Inhibicion de kinesina mitotica. |
| ATE424388T1 (de) | 2001-12-06 | 2009-03-15 | Merck & Co Inc | Mitotische kinesinhemmer |
| TW200301135A (en) | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| US7402595B2 (en) | 2002-02-13 | 2008-07-22 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| WO2003074497A1 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
| DE60315615T2 (de) | 2002-04-03 | 2008-10-02 | Bristol-Myers Squibb Co. | Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen |
| RU2004135392A (ru) | 2002-05-06 | 2005-06-27 | Дженелэбс Текнолоджиз, Инк. (Us) | Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| DE60322920D1 (de) | 2002-08-13 | 2008-09-25 | Shionogi & Co | Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung |
| JP4190232B2 (ja) | 2002-08-26 | 2008-12-03 | 富士通株式会社 | 機械研磨を行う方法 |
| US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| CA2507100C (en) | 2002-11-21 | 2012-10-09 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| US7494987B2 (en) | 2002-11-25 | 2009-02-24 | Mochida Pharmaceutical Co., Ltd. | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP4500689B2 (ja) | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
| CZ294538B6 (cs) | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
| RU2233842C1 (ru) | 2003-01-13 | 2004-08-10 | Петров Владимир Иванович | Производные пурина, обладающие противовирусной активностью |
| AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| SE0300908D0 (sv) | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| CA2524376A1 (en) | 2003-05-05 | 2004-12-16 | Neurogen Corporation | Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands |
| EP1636225B1 (en) | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| JP4570015B2 (ja) | 2003-07-14 | 2010-10-27 | クミアイ化学工業株式会社 | ２−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤 |
| AU2004264419B2 (en) | 2003-08-15 | 2009-01-15 | Irm Llc | 6-substituted anilino purines as RTK inhibitors |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| CN1856474A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
| WO2005091857A2 (en) | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
| CN1560035A (zh) | 2004-03-12 | 2005-01-05 | 沈阳药科大学 | 5－羟基吲哚－3－羧酸脂类衍生物 |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| JP2007531729A (ja) | 2004-04-02 | 2007-11-08 | アデノシン、セラピューティックス、リミテッド、ライアビリティ、カンパニー | Ａ２ａアデノシンレセプターの選択的アンタゴニスト |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| CN101023082A (zh) | 2004-07-22 | 2007-08-22 | 阿斯利康(瑞典)有限公司 | 用于治疗和预防癌症的稠合嘧啶酮类 |
| KR20070046176A (ko) | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도 |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| MX2007004699A (es) | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
| WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| MX2007016270A (es) | 2005-06-27 | 2008-03-05 | Amgen Inc | Compuestos aril nitrilo anti-inflamatorios. |
| FR2889192A1 (fr) | 2005-07-27 | 2007-02-02 | Cytomics Systems Sa | Composes antifongiques, compositions contenant ces composes et leurs utilisations |
| US20070066624A1 (en) | 2005-08-16 | 2007-03-22 | Anormed, Inc. | Chemokine receptor binding compounds |
| US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
| GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| MX391408B (es) | 2005-11-01 | 2025-03-21 | Impact Biomedicines Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
| EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
| DE602006018057D1 (de) | 2005-11-10 | 2010-12-16 | Chemocentryx Inc | Substituierte chinolone und verwendungsverfahren |
| SI1966202T1 (sl) | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US20100227880A1 (en) | 2006-01-25 | 2010-09-09 | Kristjan Gudmundsson | Chemical compounds |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| US20090069304A1 (en) | 2006-03-03 | 2009-03-12 | Shionogi & Co., Ltd. | Mmp-13 selective inhibitor |
| US20100273776A1 (en) | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| KR20120051760A (ko) | 2006-04-04 | 2012-05-22 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| DE102006029074A1 (de) * | 2006-06-22 | 2007-12-27 | Friedrich-Schiller-Universität Jena | 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| EP2044086A2 (en) | 2006-06-30 | 2009-04-08 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
| US20080009508A1 (en) | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
| EP2046788A1 (en) | 2006-07-12 | 2009-04-15 | Syngeta Participations AG | Triazolopyridine derivatives as herbicides |
| AU2007282535B9 (en) | 2006-08-08 | 2013-06-20 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivative as PI3K inhibitor and use thereof |
| ES2549862T3 (es) | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP1972631A1 (en) | 2007-03-23 | 2008-09-24 | Novartis AG | Imidazopyridazines as PI3K lipid kinase inhibitors |
| WO2008055013A2 (en) | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| EP2097422A4 (en) | 2006-11-13 | 2010-04-14 | Lilly Co Eli | THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS |
| PL2497470T3 (pl) | 2006-11-22 | 2016-04-29 | Incyte Holdings Corp | Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| PL2125827T3 (pl) | 2006-12-29 | 2011-04-29 | Hoffmann La Roche | Pochodne azaspiro |
| AU2008213836A1 (en) | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| CN101687789A (zh) | 2007-02-12 | 2010-03-31 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
| PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| EP2132207A2 (en) | 2007-03-23 | 2009-12-16 | Amgen Inc. | Heterocyclic compounds and their uses |
| PL2137186T3 (pl) | 2007-03-23 | 2016-09-30 | Związki heterocykliczne i ich zastosowania | |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US8088385B2 (en) | 2007-06-18 | 2012-01-03 | University Of Louisville Research Foundation Inc. | PFKB3 inhibitor for the treatment of a proliferative cancer |
| EP2170888B1 (en) | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CA2696113A1 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| JP2009076865A (ja) | 2007-08-29 | 2009-04-09 | Fujifilm Corp | 有機電界発光素子 |
| WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
| JP2009080233A (ja) | 2007-09-26 | 2009-04-16 | Kyocera Mita Corp | 電子写真感光体 |
| CZ300774B6 (cs) | 2007-10-05 | 2009-08-05 | Univerzita Palackého | Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny |
| WO2009062118A2 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| WO2009063235A1 (en) | 2007-11-13 | 2009-05-22 | Astrazeneca Ab | Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018 |
| JP2009120686A (ja) | 2007-11-14 | 2009-06-04 | Toyo Ink Mfg Co Ltd | 光重合開始剤、重合性組成物、および重合物の製造方法。 |
| PE20091268A1 (es) | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
| CN101945871A (zh) | 2007-12-21 | 2011-01-12 | 惠氏有限责任公司 | 咪唑并[1，2-a]吡啶化合物 |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2009081105A2 (en) | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
| US7960397B2 (en) | 2007-12-28 | 2011-06-14 | Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions |
| EP2228370B1 (en) | 2007-12-28 | 2012-05-23 | Topharman Shanghai Co., Ltd. | N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof |
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| GEP20135780B (en) | 2008-01-11 | 2013-03-11 | Natco Pharma Ltd | Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| ES2494365T3 (es) | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
| JPWO2009128520A1 (ja) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する複素環化合物 |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| WO2009140215A2 (en) | 2008-05-11 | 2009-11-19 | Geraghty, Erin | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds |
| WO2009151972A1 (en) | 2008-05-28 | 2009-12-17 | , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command | Small molecule inhibitors of botulinum neurotoxins |
| US20110294836A1 (en) | 2008-06-20 | 2011-12-01 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| US8026271B2 (en) | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
| WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
| EP2346508B1 (en) * | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
| EP2355828B1 (en) | 2008-11-13 | 2018-05-30 | Gilead Calistoga LLC | Therapies for hematologic malignancies |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| AU2009330821B2 (en) | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
| EP2387575B1 (en) | 2009-01-15 | 2013-09-04 | Anvyl, LLC | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2010092340A1 (en) | 2009-02-13 | 2010-08-19 | Ucb Pharma S.A. | Fused pyridine and pyrazine derivatives as kinase inhibitors |
| CA2756808A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-piperidine compounds |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| CA2762174C (en) | 2009-05-22 | 2018-02-20 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2010266064A1 (en) | 2009-06-25 | 2012-01-19 | Amgen Inc. | 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors |
| MX2011013510A (es) | 2009-06-25 | 2012-03-07 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| SG177384A1 (en) | 2009-06-29 | 2012-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| EA201270184A1 (ru) | 2009-07-21 | 2012-08-30 | ГИЛИЭД КАЛИСТОГА ЭлЭлСи | Лечение расстройств печени ингибиторами pi3k |
| WO2011025889A1 (en) | 2009-08-28 | 2011-03-03 | Takeda Pharmaceutical Company Limited | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| CN102666545B (zh) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
| KR101793300B1 (ko) | 2009-10-22 | 2017-11-02 | 길리애드 사이언시즈, 인코포레이티드 | 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체 |
| KR102012398B1 (ko) | 2009-11-05 | 2019-08-20 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
| EA020153B1 (ru) | 2009-11-10 | 2014-09-30 | Пфайзер Инк. | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ |
| US8957090B2 (en) | 2009-11-12 | 2015-02-17 | Ucb Pharma S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| WO2011058111A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Aminopurine derivatives as kinase inhibitors |
| CN102812033B (zh) | 2009-12-10 | 2015-11-25 | 中国医学科学院药物研究所 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| US8633313B2 (en) | 2009-12-18 | 2014-01-21 | Amgen Inc. | Heterocyclic compounds and their uses |
| AR079725A1 (es) * | 2009-12-23 | 2012-02-15 | Palau Pharma Sa | Derivados de aminoalquilpirimidina como antagonistas del receptor h4 |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| IN2012DN06323A (enExample) | 2010-01-07 | 2015-10-02 | Dow Agrosciences Llc | |
| UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| EP3715347B1 (en) | 2010-03-10 | 2021-12-22 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| MA34075B1 (fr) | 2010-03-22 | 2013-03-05 | Glenmark Pharmaceuticals Sa | Composition pharmaceutique comprenant un dérivé pyrimidineone |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| NZ603686A (en) | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CA2802484A1 (en) | 2010-06-11 | 2011-12-15 | Gilead Calistoga Llc | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| US8759371B2 (en) | 2010-07-01 | 2014-06-24 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2012003274A1 (en) | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| WO2012003271A1 (en) | 2010-07-02 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| US20130324561A1 (en) | 2010-09-24 | 2013-12-05 | Gilead Calistroga Llc. | Atropisomers of p13k-inhibiting compounds |
| CA2815445A1 (en) | 2010-11-04 | 2012-05-10 | Amgen Inc. | 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k-delta inhibitors |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| JP2013543000A (ja) | 2010-11-17 | 2013-11-28 | アムジエン・インコーポレーテツド | 複素環化合物およびその使用 |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| EP2651404B1 (en) | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Casein kinase 1delta (ck1delta) inhibitors |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| CA2822590A1 (en) | 2010-12-23 | 2012-06-28 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| TWI577676B (zh) | 2011-06-20 | 2017-04-11 | 英塞特控股公司 | 作為ｊａｋ抑制劑之吖丁啶基苯基、吡啶基或吡基羧醯胺衍生物 |
| JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| PL3196202T3 (pl) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corporation | Heterocykloaminy jako inhibitory pi3k |
| CA2850763A1 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| MX2015005428A (es) | 2012-11-01 | 2015-07-21 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak). |
| TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
| MX380171B (es) | 2013-03-15 | 2025-03-12 | Janssen Pharmaceutica Nv | Procesos e intermedios para preparar un medicamento. |
| WO2014186706A1 (en) | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
| NZ725778A (en) | 2014-04-08 | 2023-04-28 | Incyte Holdings Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| MX2016014861A (es) | 2014-05-27 | 2017-04-06 | Almirall Sa | Uso medico. |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MD3831833T2 (ro) | 2015-02-27 | 2023-04-30 | Incyte Holdings Corp | Procedee pentru prepararea unui inhibitor PI3K |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US20160362424A1 (en) | 2015-05-11 | 2016-12-15 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
-
2012
- 2012-08-31 PL PL16199883T patent/PL3196202T3/pl unknown
- 2012-08-31 ME MEP-2019-105A patent/ME03397B/me unknown
- 2012-08-31 MX MX2020004502A patent/MX389479B/es unknown
- 2012-08-31 EP EP16199883.6A patent/EP3196202B1/en active Active
- 2012-08-31 SM SM20170111T patent/SMT201700111T1/it unknown
- 2012-08-31 EA EA201791929A patent/EA033646B1/ru unknown
- 2012-08-31 LT LTEP18215449.2T patent/LT3513793T/lt unknown
- 2012-08-31 TW TW107136772A patent/TWI673272B/zh active
- 2012-08-31 TW TW105111882A patent/TWI619714B/zh active
- 2012-08-31 KR KR1020237007424A patent/KR20230038593A/ko active Pending
- 2012-08-31 LT LTEP12775861.3T patent/LT2751109T/lt unknown
- 2012-08-31 AU AU2012301721A patent/AU2012301721B2/en active Active
- 2012-08-31 HU HUE16199883A patent/HUE043703T2/hu unknown
- 2012-08-31 KR KR1020227007113A patent/KR102507287B1/ko active Active
- 2012-08-31 HU HUE12775861A patent/HUE030869T2/en unknown
- 2012-08-31 ES ES12775861.3T patent/ES2616477T3/es active Active
- 2012-08-31 KR KR1020207018981A patent/KR102249236B1/ko active Active
- 2012-08-31 KR KR1020197028988A patent/KR102131612B1/ko active Active
- 2012-08-31 CN CN201610946568.1A patent/CN106986867B/zh active Active
- 2012-08-31 MX MX2014002360A patent/MX360262B/es active IP Right Grant
- 2012-08-31 RS RS20210409A patent/RS61761B1/sr unknown
- 2012-08-31 RS RS20170191A patent/RS55737B1/sr unknown
- 2012-08-31 PE PE2018000759A patent/PE20181272A1/es unknown
- 2012-08-31 SI SI201231917T patent/SI3513793T1/sl unknown
- 2012-08-31 WO PCT/US2012/053398 patent/WO2013033569A1/en not_active Ceased
- 2012-08-31 MY MYPI2014000585A patent/MY179332A/en unknown
- 2012-08-31 EA EA201490541A patent/EA028890B1/ru unknown
- 2012-08-31 DK DK12775861.3T patent/DK2751109T3/en active
- 2012-08-31 EP EP12775861.3A patent/EP2751109B1/en active Active
- 2012-08-31 KR KR1020197011240A patent/KR102030609B1/ko active Active
- 2012-08-31 PH PH1/2021/552978A patent/PH12021552978A1/en unknown
- 2012-08-31 ES ES21158471T patent/ES3036260T3/es active Active
- 2012-08-31 JP JP2014528654A patent/JP6067709B2/ja active Active
- 2012-08-31 SI SI201230871A patent/SI2751109T1/sl unknown
- 2012-08-31 PT PT16199883T patent/PT3196202T/pt unknown
- 2012-08-31 NZ NZ769326A patent/NZ769326A/en unknown
- 2012-08-31 EP EP18215449.2A patent/EP3513793B1/en active Active
- 2012-08-31 ES ES18215449T patent/ES2873001T3/es active Active
- 2012-08-31 IL IL314671A patent/IL314671A/en unknown
- 2012-08-31 DK DK18215449.2T patent/DK3513793T3/da active
- 2012-08-31 SI SI201231554T patent/SI3196202T1/sl unknown
- 2012-08-31 CA CA2846652A patent/CA2846652C/en active Active
- 2012-08-31 SG SG10201912484RA patent/SG10201912484RA/en unknown
- 2012-08-31 PT PT127758613T patent/PT2751109T/pt unknown
- 2012-08-31 SM SM20190243T patent/SMT201900243T1/it unknown
- 2012-08-31 TW TW106144503A patent/TWI648277B/zh active
- 2012-08-31 DK DK16199883.6T patent/DK3196202T3/da active
- 2012-08-31 SG SG11201400232WA patent/SG11201400232WA/en unknown
- 2012-08-31 RS RS20190445A patent/RS58817B1/sr unknown
- 2012-08-31 HU HUE18215449A patent/HUE053953T2/hu unknown
- 2012-08-31 SG SG10201601589QA patent/SG10201601589QA/en unknown
- 2012-08-31 KR KR1020147008462A patent/KR101982475B1/ko active Active
- 2012-08-31 BR BR122019020716-0A patent/BR122019020716B1/pt active IP Right Grant
- 2012-08-31 ES ES16199883T patent/ES2722524T3/es active Active
- 2012-08-31 SM SM20210288T patent/SMT202100288T1/it unknown
- 2012-08-31 TW TW110100318A patent/TWI765515B/zh active
- 2012-08-31 MX MX2018009889A patent/MX373199B/es unknown
- 2012-08-31 EP EP21158471.9A patent/EP3888657B1/en active Active
- 2012-08-31 TW TW101131936A patent/TWI543980B/zh active
- 2012-08-31 KR KR1020217013147A patent/KR102371532B1/ko active Active
- 2012-08-31 ME MEP-2017-15A patent/ME02595B/me unknown
- 2012-08-31 PH PH1/2014/500470A patent/PH12014500470B1/en unknown
- 2012-08-31 HR HRP20170285TT patent/HRP20170285T1/hr unknown
- 2012-08-31 BR BR112014004971-8A patent/BR112014004971B1/pt active IP Right Grant
- 2012-08-31 IL IL299533A patent/IL299533B2/en unknown
- 2012-08-31 PL PL18215449T patent/PL3513793T3/pl unknown
- 2012-08-31 PE PE2014000287A patent/PE20141726A1/es active IP Right Grant
- 2012-08-31 AR ARP120103232A patent/AR087760A1/es active IP Right Grant
- 2012-08-31 UA UAA201604695A patent/UA121539C2/uk unknown
- 2012-08-31 CR CR20180293A patent/CR20180293A/es unknown
- 2012-08-31 PL PL12775861T patent/PL2751109T3/pl unknown
- 2012-08-31 US US13/601,349 patent/US9199982B2/en active Active
- 2012-08-31 PT PT182154492T patent/PT3513793T/pt unknown
- 2012-08-31 LT LTEP16199883.6T patent/LT3196202T/lt unknown
- 2012-08-31 TW TW108132191A patent/TWI717002B/zh active
-
2014
- 2014-02-27 IL IL231239A patent/IL231239A/en active IP Right Grant
- 2014-02-28 CL CL2014000517A patent/CL2014000517A1/es unknown
- 2014-03-04 CR CR20140111A patent/CR20140111A/es unknown
- 2014-03-18 CO CO14058225A patent/CO6910199A2/es active IP Right Grant
- 2014-03-28 EC ECSP14013274 patent/ECSP14013274A/es unknown
-
2015
- 2015-10-01 US US14/872,881 patent/US9730939B2/en active Active
- 2015-10-01 US US14/872,918 patent/US9707233B2/en active Active
-
2016
- 2016-09-29 JP JP2016191928A patent/JP6263591B2/ja active Active
- 2016-12-21 JP JP2016248325A patent/JP6266743B2/ja active Active
-
2017
- 2017-02-16 SM SM201700111T patent/SMT201700111B/it unknown
- 2017-02-24 CY CY20171100264T patent/CY1118679T1/el unknown
- 2017-05-09 IL IL252184A patent/IL252184B/en active IP Right Grant
- 2017-07-20 AU AU2017206260A patent/AU2017206260B2/en active Active
- 2017-08-10 US US15/673,529 patent/US10092570B2/en active Active
- 2017-09-26 PH PH12017501766A patent/PH12017501766B1/en unknown
- 2017-12-20 JP JP2017243651A patent/JP6427257B2/ja active Active
-
2018
- 2018-02-18 IL IL257576A patent/IL257576B/en active IP Right Grant
- 2018-08-24 US US16/112,160 patent/US10376513B2/en active Active
- 2018-10-26 JP JP2018201775A patent/JP6574039B2/ja active Active
-
2019
- 2019-02-28 AU AU2019201423A patent/AU2019201423B2/en active Active
- 2019-05-02 HR HRP20190824TT patent/HRP20190824T1/hr unknown
- 2019-05-21 CY CY20191100541T patent/CY1121651T1/el unknown
- 2019-06-19 US US16/446,098 patent/US10646492B2/en active Active
- 2019-07-25 ZA ZA2019/04877A patent/ZA201904877B/en unknown
- 2019-08-14 JP JP2019148821A patent/JP7038685B2/ja active Active
- 2019-09-27 PH PH12019502246A patent/PH12019502246A1/en unknown
-
2020
- 2020-03-05 IL IL273079A patent/IL273079B/en unknown
- 2020-03-05 IL IL284539A patent/IL284539B2/en unknown
- 2020-03-24 US US16/828,315 patent/US11433071B2/en active Active
-
2021
- 2021-01-18 AU AU2021200266A patent/AU2021200266B2/en active Active
- 2021-04-21 HR HRP20210627TT patent/HRP20210627T1/hr unknown
- 2021-05-19 CY CY20211100435T patent/CY1124168T1/el unknown
- 2021-12-24 JP JP2021210253A patent/JP7384891B2/ja active Active
-
2022
- 2022-07-18 US US17/866,942 patent/US11819505B2/en active Active
- 2022-12-22 AU AU2022291574A patent/AU2022291574B2/en active Active
-
2023
- 2023-10-03 US US18/376,346 patent/US12201636B2/en active Active
- 2023-11-09 JP JP2023191694A patent/JP7714616B2/ja active Active
-
2024
- 2024-11-27 US US18/962,341 patent/US20250325550A1/en active Pending
-
2025
- 2025-06-26 AU AU2025204814A patent/AU2025204814A1/en active Pending
- 2025-07-16 JP JP2025119353A patent/JP2025142039A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018044008A5 (enExample) | ||
| JP2019011375A5 (enExample) | ||
| JP2017052805A5 (enExample) | ||
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| HRP20210627T1 (hr) | Heterociklilamini kao inhibitori pi3k | |
| JP2013523884A5 (enExample) | ||
| JP2011511034A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| CA3077499C (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| JP2010510319A5 (enExample) | ||
| JP2012532131A5 (enExample) | ||
| JP2018500376A5 (enExample) | ||
| JP2013528204A5 (enExample) | ||
| JP2021502356A5 (enExample) | ||
| JP2018522859A5 (enExample) | ||
| RU2013143747A (ru) | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения | |
| JP2019515903A5 (enExample) | ||
| JP2018524331A5 (enExample) | ||
| JP2014533745A5 (enExample) | ||
| JP2019535664A5 (enExample) | ||
| JP2014527959A5 (enExample) | ||
| RU2015139590A (ru) | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ | |
| KR20100089082A (ko) | 조합 059 | |
| JP2000159672A (ja) | 硝酸誘発耐性の処置剤 | |
| JP2016537384A5 (enExample) |